What's the (end) point?

European Respiratory Journal

Volumn 45, Issue 3, 2015, Pages 853-854

  Ventetuolo, Corey E ^a   Kawut, Steven M ^b,c  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HUMAN; LETTER; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL PERFORMANCE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RISK FACTOR; SURVIVAL; TREATMENT RESPONSE; VALIDATION STUDY; FEMALE; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MALE;

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE;

ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS I;

EID: 84924006851     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00191314     Document Type: Letter

References (14)

1. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D73-D81.
2. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
3. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-613.
4. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-1029.
5. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-178.
6. Ploegstra M-J, Douwes JM, Roofthooft MTR, et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J 2014; 44: 1616-1626.
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
8. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
9. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
10. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
11. Ventetuolo CE, Gabler NB, Fritz JS, et al. Are hemodynamics surrogate end points in pulmonary arterial hypertension? Circulation 2014; 130: 768-775.
12. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126: 349-356.
13. Savarese G, Musella F, D'Amore C, et al. Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension. Eur Respir J 2013; 42: 414-424.
14. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.